Interferon-beta (IFNb), a first-line disease modifying therapy for relapsing-remitting multiple sclerosis (RRMS), has demonstrated beneficial effects on reducing clinical and radiological disease activity [1], [2], [3]. Here, IFNB1 is linked to relapsing-remitting multiple sclerosis.